At the A. Menarini-sponsored symposium, held during the 8thAssociation of South-East Asian Pain Societies (ASEAPS)Congress at Pullman Hotel Kuching, Malaysia, the importance ofa multidisciplinary approach in the management of osteoarthritis(OA) was discussed. A distinguished panel of speakers reviewedthe role of various types of treatments in the management of OAthrough a hypothetical patient case scenario, and shared theirinsights into some questions commonly asked by physicians,including their recommended strategies for pre- and postsurgeryanaesthesia and analgesia
Influenza infection is often times underrecognised and underdiagnosed in Malaysia even though it may occur at anytime of the year, unlike in temperate countries. Smoking is a well-established risk factor for influenza infection, and it is associated with a more severe disease course, morbidity and mortality. The National Avian Influenza Surveillance System of Thailand reported that current or former smoking is among the risk factors associated with a fatal outcome in patients with influenza.
Topical silicone gel is considered first-line therapy against scars and is used particularly for the treatment of elevated scars,such as hypertrophic and keloid scars. In this report, Dr Yong shares his clinical experience of using silicone gel as part of his scar management strategies.
Jointly organized by the Malaysian Medical Associationand AstraZeneca to commemorate the launch of QTERN,the Q-UEST Symposium saw three distinguished speakersproviding valuable insights into the landscape of T2DMin Malaysia and discussing the latest treatment optionsavailable in the country.
Annual inactivated influenza vaccination is recommendedfor children with chronic asthma owing to its role indecreasing the severity of disease, complications andsecondary infections. In a resource-limited setting, thissegment of patients should be prioritized to receiveinfluenza vaccinations.
Hypertension (HPT) is defined as a persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater, taken at least twice ontwo separate occasions. The most recent National Health and Morbidity Survey (NHMS) 2015 that focuses on noncommunicable diseases showed that among adults aged 18 years and older, there was an increase in the prevalence of HPT from 33.6% in 2011 to 35.3%. While the proportion of patients with HPT who have attained good BP control has increased from 34.7% in 2011 to 37.4%, the awareness of the condition among patients remains poor. The prevalence of undiagnosed HPT remains high; hence, it is recommended that every adult aged 18 years and older to check their BP at least once annually, and more frequently in those with risk factors (eg, family history, obese).
The prevalence of non-communicable diseases (NCDs) in Malaysia is on the rise.The main NCDs in Malaysia include hypertension (HPT), diabetes mellitus (DM), and cardiovascular disease (CVD), and they account for 74% of all deaths according to WHO’s NCD country profile 2018 (35% CVD, 16% cancer, 4% chronic respiratory disease, and 16% other NCDs). According to the 2015 National Health and Morbidity Survey, the overall prevalence of three major NCDs, ie, diabetes (17.5%), hypertension (30.3%) and hypercholesterolaemia (47.7%), remained high among Malaysians.
Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).